| Issue Date | Title | Author(s) |
| 25-Oct-2022 | Bifunctional anti-PD-L1/TGF-beta RII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial | Liu, Dan; Zhou, Jun; Wang, Yongsheng; Li, Mingjun; Jiang, Haiping; Liu, Yunpeng; Yin, Xianli; Ge, Minghua; Xiang, Xiaojun; Ying, Jieer; Huang, Jian; Zhang, Yan-qiao; Cheng, Ying; Huang, Zhigang; Yuan, Xianglin; Han, Weiqing; Yan, Dong; Wang, Xinshuai; Liu, Pan; Wang, Linna; Zhang, Xiaojing; Luo, Suxia; Liu, Tianshu; Shen, Lin |
| 2019 | Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial. | Shen, Lin; Peng, Zhi; Zhang, Yan-Qiao; Wei, Jia; Wang, Feng; Ying, Jieer; Deng, Yanhong; Gu, Kangsheng; Cheng, Ying; Yuan, Xianglin; Xiao, Juxiang; Wang, Linna; Zou, Jianjun |
| 1-Jun-2021 | Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction | Peng, Zhi; Wei, Jia; Wang, Feng; Ying, Jieer; Deng, Yanhong; Gu, Kangsheng; Cheng, Ying; Yuan, Xianglin; Xiao, Juxiang; Tai, Yanfei; Wang, Linna; Zou, Jianjun; Zhang, Yanqiao; Shen, Lin |
| 13-Aug-2021 | Clinicopathological Characteristics and Prognosis of Signet Ring Gastric Cancer: A Population-Based Study | Wei, Qing; Gao, Yiding; Qi, Changsong; Yuan, Xing; Li, Jingjing; Xu, Qi; Luo, Cong; Chen, Lei; Zhuo, Wei; Xu, Zhiyuan; Ying, Jieer |
| Oct-2021 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study | Peng, Zhi; Liu, Tianshu; Wei, Jia; Wang, Airong; He, Yifu; Yang, Liuzhong; Zhang, Xizhi; Fan, Nanfeng; Luo, Suxia; Li, Zhen; Gu, Kangsheng; Lu, Jianwei; Xu, Jianming; Fan, Qingxia; Xu, Ruihua; Zhang, Liangming; Li, Enxiao; Sun, Yuping; Yu, Guohua; Bai, Chunmei; Liu, Yong; Zeng, Jiangzheng; Ying, Jieer; Liang, Xinjun; Xu, Nong; Gao, Chao; Shu, Yongqian; Ma, Dong; Dai, Guanghai; Li, Shengmian; Deng, Ting; Cui, Yuehong; Fang, Jianmin; Ba, Yi; Shen, Lin |
| 2017 | Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study | Xu, Ruihua; Yu, Xianjun; Hao, Jihui; Wang, Liwei; Pan, Hongming; Han, Guohong; Xu, Jianming; Zhang, Yanqiao; Yang, Shujun; Chen, Jia; Ying, Jieer; Dai, Guanghai; Li, Mingyu; Begic, Damir; Lu, Brian; Shen, Lin |
| 20-May-2020 | Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors. | Bai, Chunmei; Xu, Jianming; Shen, Lin; Li, Jie; Zhou, Zhiwei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Ying, Jieer; Li, Jing; Fan, Songhua; Peng, Mengye; Su, Weiguo |
| 2023 | PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study | Chen, Mifen; Wang, Zhenghang; Liu, Zimin; Deng, Ting; Wang, Xiaodong; Chang, Zhiwei; Zhang, Qi; Yang, Wenlei; Liu, Ning; Ji, Zhi; Zhang, Xiaotian; Wang, Xicheng; Peng, Zhi; Li, Yi; Cao, Yujuan; Jin, Xuan; Lu, Hongxia; Qu, Huajun; Tang, Yong; Xu, Chunlei; Fang, Weijia; Zhang, Hangyu; Yan, Dong; Wang, Li; Li, Jiayi; Zhang, Jingdong; Wang, Qiwei; Xue, Liying; Yin, Fei; Han, Guangjie; Cheng, Zhiqiang; Liu, Qing; Jin, Yongdong; Zhang, Yinjie; Li, Lanxing; Cao, Baoshan; Yao, Yanhong; Chen, Zhiyu; Zou, Jianling; Ying, Jieer; Wei, Qing; Tian, Tiantian; Zhao, Weifeng; Li, Longmei; Zhang, Tong; Song, Fanghua; Ba, Ya-er; Li, Na; Gao, Hui; Ji, Yinghua; Bao, Liying; Zhao, Xiaochen; Cai, Jinping; Yuan, Zheping; Shen, Lin; Li, Jian |
| 2023 | PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study | Chen, Mifen; Wang, Zhenghang; Liu, Zimin; Deng, Ting; Wang, Xiaodong; Chang, Zhiwei; Zhang, Qi; Yang, Wenlei; Liu, Ning; Ji, Zhi; Zhang, Xiaotian; Wang, Xicheng; Peng, Zhi; Li, Yi; Cao, Yujuan; Jin, Xuan; Lu, Hongxia; Qu, Huajun; Tang, Yong; Xu, Chunlei; Fang, Weijia; Zhang, Hangyu; Yan, Dong; Wang, Li; Li, Jiayi; Zhang, Jingdong; Wang, Qiwei; Xue, Liying; Yin, Fei; Han, Guangjie; Cheng, Zhiqiang; Liu, Qing; Jin, Yongdong; Zhang, Yinjie; Li, Lanxing; Cao, Baoshan; Yao, Yanhong; Chen, Zhiyu; Zou, Jianling; Ying, Jieer; Wei, Qing; Tian, Tiantian; Zhao, Weifeng; Li, Longmei; Zhang, Tong; Song, Fanghua; Ba, Ya-er; Li, Na; Gao, Hui; Ji, Yinghua; Bao, Liying; Zhao, Xiaochen; Cai, Jinping; Yuan, Zheping; Shen, Lin; Li, Jian |
| Nov-2020 | Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study | Xu, Jianming; Shen, Lin; Zhou, Zhiwei; Li, Jie; Bai, Chunmei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Ying, Jieer; Yu, Xianjun; Qin, Shukui; Yuan, Xianglin; Zhang, Tao; Deng, Yanhong; Xiu, Dianrong; Cheng, Ying; Tao, Min; Jia, Ru; Wang, Wei; Li, Jing; Fan, Songhua; Peng, Mengye; Su, Weiguo |
